PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 478 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Can Chemotherapy Drugs Be Designed to Avoid Side Effects? December 16, 2022 Teacher Visits Student Battling Cancer At Home To Help With His... August 10, 2021 How to Find the Right Hospice Care Program for You or... August 10, 2023 Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with... February 8, 2023 Load more HOT NEWS A Remarkable Group of Patients with Haematological Disorders with No or... BRCA Gene Testing: Risks, Benefits, Costs, and Coverage Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... 7 Practical Tips for Taking Long-Term Medication
